The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2020

Filed:

Dec. 22, 2017
Applicant:

Arexis Ab, Stockholm, SE;

Inventors:

Cynthia N. Oliver, North Potomac, MD (US);

Erica Shane, McLean, VA (US);

Benjamin S. Isaacs, Andover, MA (US);

Christian B. Allan, Brookeville, MD (US);

Stephen T. Chang, Frederick, MD (US);

Assignee:

Arexis AB, Stockholm, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/10 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); C07K 16/00 (2006.01); A61K 39/42 (2006.01); A61K 47/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1027 (2013.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 39/39591 (2013.01); A61K 39/42 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); C07K 16/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.


Find Patent Forward Citations

Loading…